These elevated FGF21 levels in MASH patients likely reflect a compensatory response to metabolic stress, underscoring its role as a key regulator in conditions of hepatic and systemic dysfunction. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.